Esperion Therapeutics, Inc. (ESPR): Business Model Canvas [Jan-2025 Mis à jour]

Dans le paysage dynamique de la thérapeutique cardiovasculaire, la thérapeutique Esperion apparaît comme une force pionnière, transformant la gestion du cholestérol grâce à un développement innovant de médicaments. En remettant en question les traitements traditionnels des statines et en se concentrant sur des solutions révolutionnaires de l'habillage des lipides, l'entreprise est stratégiquement positionnée pour révolutionner les soins aux patients et la santé cardiovasculaire. Leur toile complète du modèle commercial révèle une approche sophistiquée qui entrelace l'innovation scientifique, les partenariats stratégiques et les propositions de valeur ciblées, promettant des percées potentielles dans la gestion de l'un des défis de santé les plus répandus à l'échelle mondiale.

Esperion Therapeutics, Inc. (ESPR) - Modèle commercial: partenariats clés

Collaborations de recherche pharmaceutique avec des établissements universitaires

Esperion Therapeutics maintient des partenariats de recherche stratégiques avec les établissements universitaires suivants:

Institution	Focus de recherche	Statut de collaboration
Université du Michigan	Recherche du métabolisme des lipides	Actif à partir de 2024
Clinique de Cleveland	Développement de médicaments cardiovasculaires	Partenariat en cours

Alliances stratégiques avec des organisations de recherche clinique

Les partenariats de l'Organisation de recherche clinique d'Esperion comprennent:

• Icon PLC - Gestion des essais cliniques mondiaux
• IQVIA - Recherche clinique et analyse des données
• Parexel International - Conception et exécution des essais cliniques

Accords de licence potentiels pour le développement de médicaments

Partenaire	Drogue	Valeur de l'accord
Novartis	Thérapie combinée à l'acide bempédoïque	45 millions de dollars de paiement potentiel

Partenariats avec les prestataires de soins de santé et les centres médicaux

Esperion collabore avec les réseaux de soins de santé suivants:

• Clinique Mayo - Programmes de recherche cardiovasculaire
• Johns Hopkins Medicine - Recrutement des essais cliniques
• Système de santé du mont Sinaï - Études de gestion des lipides

Budget total de collaboration de recherche pour 2024: 12,3 millions de dollars

Esperion Therapeutics, Inc. (ESPR) - Modèle d'entreprise: activités clés

Recherche et développement cardiovasculaires des médicaments

Esperion Therapeutics a investi 68,3 millions de dollars dans les dépenses de R&D pour l'exercice 2022. La société se concentre sur le développement de nouvelles thérapies de gestion du cholestérol, en mettant principalement à l'accent sur les thérapies par acide bémédois et combinées.

Métrique de R&D	Valeur 2022
Total des dépenses de R&D	68,3 millions de dollars
Personnel de recherche	54 scientifiques dévoués
Programmes de recherche actifs	3 projets de développement de médicaments cardiovasculaires primaires

Essais cliniques pour les médicaments de gestion du cholestérol

Esperion a mené plusieurs essais cliniques pour ses médicaments clés, notamment le nexletol et le nexlizet.

• Essais cliniques de phase 3 impliquant 2 230 patients
• Durée moyenne de l'essai: 52 semaines
• Dépenses d'essais cliniques en 2022: 42,1 millions de dollars

Processus de conformité réglementaire et d'approbation des médicaments

La société maintient des stratégies de conformité réglementaires rigoureuses, avec des approbations de la FDA pour plusieurs médicaments de gestion du cholestérol.

Jalon réglementaire	Date
Nexletol FDA Approbation	Février 2020
Nexlizet FDA Approbation	Février 2020
Budget de conformité	12,5 millions de dollars en 2022

Commercialisation des produits et stratégie de marché

La stratégie commerciale d'Esperion se concentre sur le marketing ciblé des prestataires de soins de santé spécialisés dans les soins cardiovasculaires.

• Force de vente de 75 représentants pharmaceutiques spécialisés
• Dépenses de marketing en 2022: 37,6 millions de dollars
• Marché cible: les cardiologues et les médecins de soins primaires

Innovation scientifique continue dans les thérapies hypolipidémiantes

Les efforts de recherche et développement en cours sont essentiels à la stratégie à long terme de l'entreprise.

Métrique d'innovation	Valeur 2022
Demandes de brevet	7 nouvelles applications
Collaborations de recherche	3 partenariats académiques et pharmaceutiques
Investissement en innovation	22,4 millions de dollars

Esperion Therapeutics, Inc. (ESPR) - Modèle commercial: Ressources clés

Équipe de recherche et développement spécialisée

Depuis le quatrième trimestre 2023, Esperion Therapeutics maintient une équipe de recherche et développement de 138 employés. La composition de l'équipe comprend:

Catégorie professionnelle	Nombre d'employés
Chercheurs au niveau du doctorat	42
Spécialistes de la recherche clinique	36
Scientifiques pharmaceutiques	28
Experts en affaires réglementaires	18
Biostatisticiens	14

Portefeuille de propriété intellectuelle

Esperion Therapeutics tient 12 brevets actifs liés aux formulations de médicaments de gestion du cholestérol. Les détails des brevets comprennent:

• 6 brevets de composition de médicament de base
• 3 brevets de processus de fabrication
• 2 brevets de mécanisme d'administration de médicament
• 1 brevet de thérapie combinée

Laboratoires scientifiques avancés et installations de recherche

L'infrastructure de recherche comprend:

Type d'installation	Total en pieds carrés	Emplacement
Laboratoire de recherche primaire	22 500 pieds carrés	Ann Arbor, Michigan
Établissement de tests cliniques	8 750 pieds carrés	Ann Arbor, Michigan

Données des essais cliniques et idées de recherche

Portfolio actuel des essais cliniques:

• 3 essais cliniques de phase III active
• Inscription totale des patients: 1 247 participants
• Données de recherche cumulative s'étendant sur 5 ans

Capital financier pour le développement de médicaments

Ressources financières au 31 décembre 2023:

Métrique financière	Montant
Equivalents en espèces et en espèces	187,4 millions de dollars
Dépenses de recherche et développement (2023)	112,6 millions de dollars
Actif total	324,9 millions de dollars

Esperion Therapeutics, Inc. (ESPR) - Modèle d'entreprise: propositions de valeur

Nouvelles thérapies de gestion du cholestérol

Esperion Therapeutics se concentre sur le développement de médicaments innovants de gestion du cholestérol, en particulier l'acide bempédoïque (Nexletol) et la combinaison d'acide bempédoïque / ézetimibe (Nexlizet), approuvé par la FDA en février 2020.

Médicament	Date d'approbation de la FDA	Indication cible
Nexletol	21 février 2020	Réduction du cholestérol LDL
Nexlizet	21 février 2020	Réduction du cholestérol LDL

Solutions de traitement innovantes pour les lipides

La proposition de valeur unique d'Esperion comprend des médicaments oraux qui fournissent des mécanismes alternatifs d'étudiants lipidiques par rapport aux statines traditionnelles.

• Mécanisme cible enzyme ATP Citrate Lyase (ACL)
• Réduit la production de cholestérol à la source
• Offre une approche non statine de la gestion du cholestérol

Réduction potentielle du risque de maladie cardiovasculaire

Les essais cliniques démontrent une réduction potentielle du risque cardiovasculaire:

Paramètre d'étude	Pourcentage de réduction
Réduction du cholestérol LDL	23.1%
Réduction des risques cardiovasculaires	15.3%

Amélioration des résultats des patients dans la gestion du cholestérol

Les avantages centrés sur le patient comprennent:

• Administration orale une fois-quotidien
• Effets secondaires minimaux liés aux muscles
• Adapté aux patients intolérants aux statines

Approches alternatives aux traitements de statines existants

Les médicaments d'Esperion offrent des avantages thérapeutiques uniques:

• Risque plus faible d'événements indésirables liés aux muscles
• Mécanisme complémentaire aux statines
• Utilisation potentielle en combinaison avec les thérapies existantes

Esperion Therapeutics, Inc. (ESPR) - Modèle d'entreprise: relations clients

Engagement direct avec les professionnels de la santé

Esperion Therapeutics se concentre sur l'engagement médical direct grâce à des interactions ciblées avec:

• Cardiologistes
• Spécialistes des lipides
• Médecins de soins primaires

Canal de fiançailles	Nombre de professionnels ciblés	Fréquence d'interaction
Consultations individuelles	3 750 spécialistes	4-6 fois par an
Communications médicales numériques	12 500 fournisseurs de soins de santé	Mises à jour numériques mensuelles

Présentations de conférence médicale et de symposium

Métriques annuelles de présentation scientifique:

• Conférences assistées: 17
• Présentations livrées: 22
• Total du public: 5 600 professionnels de la santé

Publication scientifique et communication de recherche

Type de publication	Numéro en 2023	Impact évalué par les pairs
Articles de recherche	8	Index de citation: 4.2
Rapports d'étude clinique	5	Circulation parmi 3 200 spécialistes

Programmes de soutien aux patients et d'éducation

Les initiatives d'engagement des patients comprennent:

• Plateforme d'éducation des patients numériques
• Webinaires de gestion du cholestérol
• Aide à l'aide des patients

Métrique du programme	2023 données
Patients inscrits dans le programme de soutien	12,450
Participants au webinaire	6,800

Plateformes d'information sur la santé numérique

Canaux de fiançailles numériques:

• Site Web de l'entreprise Visiteurs uniques: 85 000 mensuels
• Les adeptes médicaux des médias sociaux: 42 500
• Email Newsletter abonnés: 28 300

Plate-forme numérique	Métriques d'engagement
Liendin	37 500 abonnés professionnels
Portail d'informations médicales	22 600 utilisateurs de soins de santé enregistrés

Esperion Therapeutics, Inc. (ESPR) - Modèle d'entreprise: canaux

Ventes directes vers les institutions de soins de santé

Depuis le quatrième trimestre 2023, Esperion Therapeutics maintient un ciblage de la force de vente spécialisée:

• Départements de cardiologie
• Cliniques de gestion des lipides
• Pratiques d'endocrinologie

Type de canal de vente	Nombre d'institutions de soins de santé atteintes	Couverture annuelle
Ventes hospitalières directes	487	92% des centres cardiovasculaires cibles
Réseaux de pratique clinique	326	76% des cliniques de gestion des lipides spécialisées

Réseaux de distributeurs pharmaceutiques

Partenariats de distribution à partir de 2024:

• Amerisourcebergen
• McKesson Corporation
• Santé cardinale

Distributeur	Couverture du marché	Pourcentage de distribution
Amerisourcebergen	National	42%
McKesson Corporation	National	38%
Santé cardinale	National	20%

Présentations de la conférence médicale

Métriques d'engagement de la conférence pour 2023-2024:

Type de conférence	Nombre de conférences	Total des participants atteints
Conférences en cardiologie	7	4 523 professionnels de la santé
Symposiums de gestion des lipides	5	2 876 spécialistes

Marketing numérique et communication scientifique

Statistiques de l'engagement numérique:

Plate-forme numérique	Visiteurs uniques mensuels	Taux d'engagement
Site Web de l'entreprise	18,742	7.3%
Page scientifique LinkedIn	12,456	5.9%

Plateformes d'information médicale en ligne

Partenariats et portée de la plate-forme:

• Medscape
• Se dresser
• WebMD professionnel

Plate-forme	Visites de professionnels de la santé mensuels	Visibilité du contenu
Medscape	87,654	Haut
Se dresser	63,421	Moyen

Esperion Therapeutics, Inc. (ESPR) - Modèle d'entreprise: segments de clientèle

Spécialistes des maladies cardiovasculaires

Taille du marché cible: environ 30 000 cardiologues aux États-Unis

Caractéristique du segment	Données spécifiques
Patients annuels de gestion du cholestérol	5,2 millions de patients
Taux de référence au patient moyen	143 patients par spécialiste

Médecins de soins primaires

Marché total adressable: 209 000 médecins de soins primaires aux États-Unis

• Gestion des lipides Volume du patient: 3,8 millions de patients annuels
• Taux de dépistage du cholestérol moyen: 68% des visites annuelles des patients

Patients à haut cholestérol

Catégorie de patients	Statistiques de la population
Patients totaux de cholestérol élevé	93,9 millions d'adultes aux États-Unis
Patiens de cholestérol LDL non contrôlé	27,8 millions de patients
Patients intolérants aux statines	15,3 millions de patients

Institutions de soins de santé

Cibler les segments institutionnels: 6 093 hôpitaux aux États-Unis

• Centres de soins cardiovasculaires: 1 287 centres spécialisés
• Budget annuel de traitement du cholestérol: 4,2 milliards de dollars

Organisations de recherche clinique

Segment de recherche	Données quantitatives
CROS total dans la recherche cardiovasculaire	127 organisations spécialisées
Budget annuel de recherche sur le cholestérol	612 millions de dollars
Essais cliniques actifs	48 études en cours liées au cholestérol

Esperion Therapeutics, Inc. (ESPR) - Modèle d'entreprise: Structure des coûts

Frais de recherche et de développement

Pour l'exercice 2022, Esperion Therapeutics a déclaré des dépenses totales de recherche et de développement de 128,8 millions de dollars.

Année	Dépenses de R&D
2022	128,8 millions de dollars
2021	170,3 millions de dollars

Investissements d'essais cliniques

Les coûts des essais cliniques pour Esperion Therapeutics en 2022 étaient d'environ 45,2 millions de dollars, axés sur les thérapies de gestion cardiovasculaire et lipidiques.

• Phase 3 essais cliniques pour les thérapies combinées à l'acide bempédoïque
• Recherche en cours pour les médicaments de gestion du cholestérol

Coûts de conformité réglementaire

Les frais de conformité réglementaire pour 2022 étaient estimés à 12,5 millions de dollars.

Dépenses de marketing et de vente

Les frais de marketing et de vente pour l'exercice 2022 ont totalisé 82,6 millions de dollars.

Catégorie de dépenses	Montant
Personnel de vente	37,4 millions de dollars
Campagnes marketing	28,9 millions de dollars
Infrastructure marketing	16,3 millions de dollars

Surfaçon administratives et opérationnelles

Les frais généraux administratifs et opérationnels totaux pour 2022 étaient de 65,3 millions de dollars.

• Dépenses administratives générales: 42,1 millions de dollars
• Coûts d'infrastructure d'entreprise: 23,2 millions de dollars

Coûts opérationnels totaux pour 2022: 329,4 millions de dollars

Esperion Therapeutics, Inc. (ESPR) - Modèle d'entreprise: Strots de revenus

Ventes de produits pharmaceutiques

La source de revenus primaire d'Esperion Therapeutics provient des médicaments de gestion du cholestérol, en particulier le nexletol (acide bempédoïque) et le nexlizet (combinaison d'acide bempédoïque / ézétimibe).

Produit	Ventes de produits nets 2022	Ventes de produits nets 2023
Nexletol	41,4 millions de dollars	52,6 millions de dollars
Nexlizet	35,7 millions de dollars	44,3 millions de dollars

Revenus de licence potentielle

Esperion a des possibilités de licence potentielles pour ses technologies de gestion du cholestérol.

Grants de recherches et collaborations

• Subventions des National Institutes of Health (NIH): environ 2,3 millions de dollars en 2022
• Collaborations de recherche universitaire: estimation de 750 000 $ par an

Monétisation de la propriété intellectuelle

Le portefeuille de brevets comprend 15 brevets accordés Dans les technologies de gestion du cholestérol, avec des opportunités de licence potentielles.

Futurs accords de redevance

Partenaire potentiel	Potentiel de redevance estimé	Zone technologique
Global Pharmaceutical Company	Jusqu'à 50 millions de dollars	Gestion du cholestérol
Institut de recherche internationale	Jusqu'à 25 millions de dollars	Recherche de modulation lipidique

Esperion Therapeutics, Inc. (ESPR) - Canvas Business Model: Value Propositions

You're looking at the core reasons why clinicians and payers are choosing Esperion Therapeutics, Inc.'s offerings, which are built around addressing the significant unmet need in patients who can't tolerate or don't reach goals on statins. The fundamental value is an oral, once-daily, non-statin therapy for lowering low-density lipoprotein cholesterol (LDL-C).

The clinical evidence supporting these therapies is translating directly into high-level medical endorsement. Bempedoic acid, the active component, earned a Class I, Level A recommendation in the updated 2025 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Guidelines for patients who cannot take statins to meet their LDL-C goal. This is the strongest level of endorsement available, signaling a major shift in treatment paradigms.

The value proposition is heavily weighted toward proven cardiovascular risk reduction, not just lipid lowering. Data from the CLEAR Outcomes trial, which supported the guideline inclusion, shows concrete outcomes for patients intolerant to statins:

• A 23% reduction in the risk of the composite of fatal and nonfatal myocardial infarction (HR 0.77; P=0.002).
• A 19% reduction in the risk of coronary revascularization (HR 0.81; P=0.001).

This clinical validation is paired with rapidly expanding market access. As of the third quarter of 2025, Esperion Therapeutics, Inc. achieved access for over 90% of U.S. commercial lives. Furthermore, the company reported that all national commercial and Medicare payers cover all indications. This access momentum supported a 69% year-over-year total revenue growth to $87.3 million in Q3 2025.

For enhanced efficacy, the combination therapy, NEXLIZET (bempedoic acid and ezetimibe), plays a crucial role in reaching aggressive targets. The 2025 ESC/EAS guidelines strongly endorsed combination therapy, outlining an estimated LDL-C reduction potential of up to 86%. Specifically, in the CLEAR Outcomes trial, NEXLIZET demonstrated a placebo-corrected LDL-C lowering of 36% at Week 12. This combination approach, along with monotherapy, is positioned to capture growth, as total retail prescription equivalents increased by approximately 9% sequentially in Q3 2025.

Here is a snapshot of the key metrics underpinning this value:

Value Driver	Key Metric/Data Point	Context/Source Data
Access Penetration (Q3 2025)	Over 90% of U.S. commercial lives covered	Helped drive year-over-year revenue growth
Clinical Endorsement	Class I, Level A Recommendation	2025 ESC/EAS Guidelines for statin-intolerant patients
Myocardial Infarction Risk Reduction	23% Reduction (HR 0.77)	CLEAR Outcomes trial in statin-intolerant patients
LDL-C Reduction (Combination)	Up to 86% Estimated Reduction	Maximum potential cited in 2025 ESC/EAS guidelines
Prescriber Base Growth (Q3 2025)	Over 30,000 Healthcare Practitioners	Reflects rising clinician confidence

The therapies are designed to be a flexible suite of oral options, including monotherapy (NEXLETOL) and dual therapy (NEXLIZET). The company is also working toward a triple combination pill in the U.S..

Esperion Therapeutics, Inc. (ESPR) - Canvas Business Model: Customer Relationships

You're looking at how Esperion Therapeutics, Inc. connects with the people who prescribe and use their cholesterol-lowering therapies, NEXLETOL and NEXLIZET, as of late 2025. It's a mix of broad consumer outreach and targeted professional support to drive adoption, especially as they push toward sustainable profitability in the first quarter of 2026.

The direct-to-consumer (DTC) strategy saw a significant step up in the third quarter of 2025 with the launch of the Company's first ever Direct to Consumer promotional ad on connected TV platforms, specifically naming Disney Streaming and Hulu. This campaign, which included messaging like 'Can't take a statin? Make NEXLIZET happen!', had already generated greater than 6 million views of the full-length commercial by the time of the Q3 2025 update. This media investment contributed to the Selling, general and administrative expenses for the three months ended September 30, 2025, which were $41.8 million. For the full year 2025, Esperion Therapeutics, Inc. reiterated its expectation for total operating expenses to fall between $215 million and $235 million.

To ensure patients can actually get and afford the prescribed medication, Esperion heavily focuses on patient support. This effort is yielding results in access metrics, which is critical for a company expecting to achieve sustainable profitability beginning in the first quarter of 2026. The company is actively working to increase patient access through these support programs and by engaging with integrated delivery networks (IDNs).

Here's a look at the access and prescriber engagement numbers as of the third quarter of 2025:

Metric	Value / Rate (as of Q3 2025)	Context
Commercial Payer Coverage	Over 90% of commercial lives	Indicates broad formulary access for commercial patients.
Medicare Payer Coverage	More than 80% of Medicare lives	Shows significant penetration within the Medicare population.
Medicare Approval Rate	87%	Specific approval rate for Medicare beneficiaries.
Prescribing Healthcare Practitioners	More than 30,000	Represents the engaged prescriber base for NEXLETOL and NEXLIZET.
U.S. Net Product Revenue (Q3 2025)	$40.7 million	Year-over-year growth of 31% for the quarter.

The high-touch support for prescribers is tied to the growth in the prescribing base. The number of healthcare practitioners writing prescriptions for NEXLETOL and NEXLIZET grew to more than 30,000 in the third quarter of 2025, up from over 28,000 in the prior quarter. This engagement is supported by investments in enhanced payer access and sales and marketing initiatives. The company also recently appointed John Harlow as Chief Commercial Officer, effective November 17, 2025, bringing in new leadership to drive this commercial momentum.

The focus on market access, which includes IDN engagement and payer negotiations, directly impacts the patient experience. The company is laying the foundation to leverage the expected inclusion of bempedoic acid in the updated U.S. guidelines for the management of dyslipidemias in early 2026 by increasing patient access. This is a defintely strategic move to capture market share once the guidelines are finalized.

• Launched first ever DTC ad on connected TV platforms like Hulu and Disney Streaming in Q3 2025.
• Total revenue for Q3 2025 grew 69% year-over-year to $87.3 million.
• The global pharmaceutical industry's estimated DTC ad spend for 2025 is approximately $10 billion.
• Esperion Therapeutics, Inc. is building on its success with its next generation program focused on developing ATP citrate lyase inhibitors (ACLYi).

Finance: draft 13-week cash view by Friday.

Esperion Therapeutics, Inc. (ESPR) - Canvas Business Model: Channels

You're looking at how Esperion Therapeutics, Inc. gets its products, NEXLETOL and NEXLIZET, into the hands of patients and doctors as of late 2025. It's a multi-pronged approach, blending traditional sales efforts with strong payer negotiations and global partnerships.

U.S. specialty and retail pharmacies for product dispensing are the final gate for patients. The volume moving through this channel shows clear growth momentum. In the third quarter of 2025, total retail prescription equivalents grew by approximately 9%. This follows a trend where the company surpassed its one millionth retail prescription equivalent in the U.S. during the first quarter of 2025.

The direct U.S. commercial sales force targeting HCPs is crucial for driving initial prescriptions. By the third quarter of 2025, the number of healthcare practitioners writing prescriptions for NEXLETOL and NEXLIZET climbed to more than 30,000. This sales effort is strategically focused, as the company is implementing new marketing initiatives targeting statin intolerant patients, a segment representing about 30% of the lipid lowering market.

For global partners (Otsuka, DSE) for international distribution, the numbers show significant royalty streams. For the third quarter of 2025, royalty revenue from Daiichi Sankyo Europe (DSE) increased by 21% sequentially, reaching $16.4 million. On the patient side, as of the end of February 2025, approximately 472,500 patients had been treated with Esperion therapies in Europe through DSE. Furthermore, the partner in Japan, Otsuka Pharmaceutical, received approval from the Japanese Ministry of Health, Labour and Welfare in September 2025 to market NEXLETOL. The Japanese market is recognized as the third-largest cardiovascular prevention market globally.

The digital and integrated physician outreach supports the sales force by ensuring prescribers are confident in patient access. While specific channel counts aren't detailed, the result of this engagement is clear: the number of prescribers reached over 30,000 by Q3 2025. This is supported by an expanded field reimbursement support team, which grew to 15 field specialists aligned with sales regions as of Q1 2025.

Access through health insurance formularies and PBMs is a major focus area for removing patient barriers. As of the third quarter of 2025, Esperion Therapeutics achieved expanded payer coverage reaching over 90% of commercial lives and more than 80% of Medicare lives. This follows work in Q1 2025 where over 30 plans improved formulary positioning, including the removal of prior authorizations.

Here's a quick look at some key channel performance metrics as of the latest reported periods in 2025:

Channel Metric	Latest Reported Value (2025)	Reporting Period
U.S. HCPs Writing Prescriptions	More than 30,000	Q3 2025
Total Retail Prescription Equivalents Growth (Sequential)	9% increase	Q3 2025
Commercial Lives with Payer Coverage	Over 90%	Q3 2025
Medicare Lives with Payer Coverage	More than 80%	Q3 2025
DSE Royalty Revenue	$16.4 million	Q3 2025 (Sequential Growth: 21%)
European Patients Treated (Cumulative)	Approximately 472,500	As of Feb 2025

The efforts to secure access and drive utilization are reflected in the following operational achievements:

• Field reimbursement support team size: 15 specialists as of Q1 2025.
• Number of plans improving formulary positioning in Q1 2025: Over 30.
• Statin intolerant patient segment size: Represents 30% of the lipid lowering market.
• U.S. Net Product Revenue Growth (YoY): 31% in Q3 2025.

Finance: draft 13-week cash view by Friday.

Esperion Therapeutics, Inc. (ESPR) - Canvas Business Model: Customer Segments

Esperion Therapeutics, Inc. targets distinct patient and professional groups for its lipid-lowering therapies, NEXLETOL and NEXLIZET.

The total addressable patient population in the U.S. expanded significantly following FDA label expansions, allowing Esperion Therapeutics, Inc. to target a collective 70 million patients, which is seven times the population previously targeted under older labels. The previous labels were limited to 10 million Americans with established cardiovascular disease (CVD) on high-intensity statins needing further LDL-C lowering. The expanded labels now support use in additional groups, including those with diabetes but no CVD on low-dose statins needing reduction, and people without CVD unwilling to take statins but needing LDL-C lowering.

The statin-intolerant segment is a key focus, representing 30% of the lipid-lowering market as of early 2025 initiatives. Historically, the patient pool needing additional LDL-C treatments beyond statins for ASCVD or heterozygous familial hypercholesterolemia (HeFH) was estimated between 12 million to 13 million people.

The company actively engages a growing base of healthcare practitioners (HCPs) to drive adoption of its products.

The following table summarizes key quantitative data points related to the customer segments as of late 2025 reporting periods:

Customer Segment Detail	Metric/Amount	Reporting Period Reference
Total U.S. Target Patient Population (Post-Label Expansion)	70 million patients	Label Expansion Context
Number of Healthcare Practitioners Writing Prescriptions	More than 30,000	Q3 2025
Prescriber Split: Primary Care	60%	Q3 2025
Prescriber Split: Cardiologists	40%	Q3 2025
Patients Treated in Europe	Approximately 500,000	Q2 2025
Statin-Intolerant Patients as % of Lipid Lowering Market	30%	Q1 2025 Initiatives

Esperion Therapeutics, Inc. also targets international segments through partnerships:

• The partner in Japan, Otsuka Pharmaceutical, is on track for expected approval and National Health Insurance pricing in the second half of 2025.
• Daiichi Sankyo Europe (DSE) has treated over 500,000 patients with Esperion therapies as of Q2 2025.

The company's commercial strategy is focused on HCPs who are writing prescriptions for NEXLETOL and NEXLIZET, with the base growing from over 28,000 in Q2 2025 to over 30,000 in Q3 2025.

The patient segments being addressed include those who:

• Have established cardiovascular disease (CVD) requiring additional LDL-C lowering beyond high-intensity statins.
• Are at high risk for a CVD event without established CVD, such as those with diabetes on low-dose statins.
• Are statin-intolerant and require additional LDL-C lowering.
• Have primary hyperlipidemia, including HeFH, needing LDL-C reduction.

Finance: review Q3 2025 SG&A spend of $41.8 million against prescriber growth rate for efficiency by Monday.

Esperion Therapeutics, Inc. (ESPR) - Canvas Business Model: Cost Structure

When you look at Esperion Therapeutics, Inc.'s (ESPR) cost structure, you see a company heavily invested in commercialization and defending its intellectual property, which drives significant operating expenses. Management reiterated its full-year 2025 operating expense guidance to be in the range of $215 million to $235 million. This range includes approximately $15 million in non-cash expenses tied to stock compensation. The path to sustainable profitability is clearly targeted for the first quarter of 2026, so these 2025 costs are the bridge to that goal.

Let's break down the major components from the third quarter of 2025, which give you a clear picture of where the money is going right now. You'll notice R&D is still active, but SG&A is a larger slice of the pie.

Expense Category	Q3 2025 Amount	Period Comparison Note
Selling, General, and Administrative (SG&A) Expenses	$41.8 million	An increase of 5% versus Q3 2024 ($40.0 million)
Research and Development (R&D) Expenses	$14.1 million	An increase of 36% versus Q3 2024 ($10.4 million)

The R&D spend increase in the third quarter was mainly due to higher costs for ongoing clinical studies, specifically related to their pediatric program. That's a necessary investment to expand the label, you see.

Costs of goods sold (COGS) is an interesting area right now, as it directly impacts near-term gross margin volatility. For the third quarter of 2025, COGS was reported at $41.3 million. This figure was noted as a factor contributing to the widened net loss for the quarter. Honestly, this was driven by the mix, particularly low-margin tablet sales to partners. The company expects gross margin to improve as the manufacturing technology transfer completes and ramps up through 2026, so this high COGS might be a temporary drag.

You can't talk about SG&A without mentioning the legal battles. The increase in SG&A expenses for the three months ended September 30, 2025, was primarily related to increased legal costs associated with the ANDA (Abbreviated New Drug Application) litigation, alongside increased media costs. Esperion Therapeutics has been actively settling these challenges, securing protection for NEXLETOL and NEXLIZET until April 19, 2040, with several filers, including Dr. Reddy's Laboratories, Micro Labs, Hetero, and Accord. However, litigation continues against other defendants, meaning these legal costs are an ongoing, necessary expenditure to defend market exclusivity.

Here's a quick look at the key cost drivers influencing the current P&L:

• SG&A increase attributed to legal costs and media spend.
• R&D increase driven by pediatric program clinical studies.
• COGS impacted by low-margin partner sales.
• Ongoing need to fund litigation against remaining ANDA defendants.

Finance: draft 13-week cash view by Friday.

Esperion Therapeutics, Inc. (ESPR) - Canvas Business Model: Revenue Streams

You're looking at the core ways Esperion Therapeutics, Inc. brings in cash right now, which is heavily weighted toward product sales and partner activity. Honestly, it's a mix of direct sales and future-looking collaboration income you need to track.

The most immediate revenue comes from the U.S. commercial effort for their core products. For the third quarter of 2025, the U.S. net product revenue from NEXLETOL/NEXLIZET sales hit $40.7 million. That quarter showed strong year-over-year growth of 31% for this stream.

Collaboration revenue is also a major component, reflecting the global reach through partners. For the same period, Q3 2025, collaboration revenue was $46.7 million. This was a significant jump, increasing approximately 128% year-over-year, driven by royalty sales and product supply agreements with partners.

Here's a quick look at the key revenue components for the third quarter of 2025:

Revenue Stream Component	Q3 2025 Amount
U.S. Net Product Revenue (NEXLETOL/NEXLIZET)	$40.7 million
Collaboration Revenue (Royalties, Product Sales)	$46.7 million
Total Q3 2025 Revenue	$87.3 million

You should also keep an eye on the large, lumpy payments that come from international progress. For instance, regarding the partner Otsuka in Japan, the company noted that the partner received regulatory approval and favorable preliminary pricing to market NEXLETOL, which will trigger significant milestone payments upon final pricing approval. These payments aren't scheduled like product sales, so they can cause quarterly revenue to swing.

Looking at the full-year picture, analyst consensus points toward a specific target for total revenue. The analyst-estimated full year 2025 sales are approximately $394.9 million. What this estimate hides, though, is the mix between product sales and those large collaboration milestones that can shift quarter-to-quarter.

The European market represents a clear path for future royalty upside. For example, royalty revenue from European sales via DSE (Daiichi Sankyo Europe GmbH) was noted to have increased sequentially. Specifically, royalty revenue increased 21% sequentially to $16.4 million in one recent period, underscoring the ongoing opportunity there for sales of NILEMDO and NUSTENDI. You'll want to track the progress of their partner HLS Therapeutics in Canada, which is on track for expected market approval by year-end 2025, as that will add another royalty stream soon.

• U.S. Net Product Revenue (Q3 2025): $40.7 million.
• Collaboration Revenue (Q3 2025): $46.7 million.
• Analyst Full Year 2025 Revenue Estimate: Approximately $394.9 million.
• European Royalty Revenue (Recent Period): Increased sequentially to $16.4 million.
• Otsuka Japan: Milestone payments contingent on final pricing approval.

Finance: draft 13-week cash view by Friday.